Quark Pharmaceuticals has recently announced that its partner Pfizer has begun a phase II clinical trial of a chemically modified small interfering RNA (siRNA) molecule in patients with diabetic macular oedema. PF-4523655 inhibits abnormal blood vessel growth and leakage independently of the VEGF pathway, reduces inflammation and suppresses apoptosis. Results from a Phase I/II trial completed by Quark on Pfizer’s behalf showed that PF-4523655 was safe and well tolerated in patients with wet age-related macular degeneration who failed to respond to currently approved therapies. The new trial will test the safety and efficacy of PF-4523655 compared with laser surgery.
siRNA molecules interfere with the expression of specific genes and there is currently much interest in using the technology to treat a wide range of diseases, although there are several challenges that must be overcome if exogenous siRNA is to become widely used.
Despite the challenges, several siRNA molecules have entered clinical trials including TD101 for pachyonychia congenita (PC Project / TransDerm), Sirna-027/AGN-745 for age-related macular degeneration (Allergan), metastatic melanoma (Duke University), CALAA-01 for solid tumours (Calando Pharmaceuticals), Cand5 for diabetic macular oedema (Opko Health) and I5NP for acute kidney injury following cardiac bypass surgery (Quark Pharmaceuticals).
Related posts:
- Proof of Concept for siRNA in Melanoma By far the majority of marketed drugs modulate the activity of proteins. Since the discovery of RNA interference (RNAi) over...
- New Clinical Trial Platform at Medpedia Launched in 2009, the Medpedia Project aims to evolve a model for sharing and advancing knowledge in health and medicine....
- siRNA Experiments Identify Ebola Virus Drug Targets Antiviral drugs that exclusively target viral factors rather than host cell processes offer the possibility of fewer side effects but...
- Plk1 in Oncology – the Case Strengthens Polo-like kinase 1 (Plk1) has received attention in recent years as a potential target for intervention in cancer. It is...
- Oral Delivery of Short Interfering RNA Molecules Although many studies have shown the potential for gene silencing using short interfering RNA (siRNA), a major hurdle to the...
Related posts brought to you by Yet Another Related Posts Plugin.
This entry was posted on Tuesday, August 5th, 2008 at 9:09 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Entries (RSS)